Anti-inflammatory Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

The Anti-Inflammatory Drugs Market Report is Segmented by Treatment (Arthritis, Chronic Obstructive Pulmonary Disease (COPD), Multiple Sclerosis, Inflammatory Bowel Disease (IBD), Asthma, Tendonitis, and Other Treatments), Drug Class (Anti-Inflammatory Biologics, Non-Steroidal Anti Inflammatory Drugs (NSAIDs), Corticosteroids, Immune-Selective Anti-Inflammatory Derivatives (ImSAID), and Other Drug Classes), Sales Channel (Prescription and Over the Counter (OTC)), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, and South America). The Report Offers Market Sizes and Forecasts for all the Above Segments in Value (USD).

Anti-inflammatory Drugs Market Size & Share Analysis - Growth Trends & Forecasts (2025 - 2030)

Anti Inflammatory Drugs Market Size

Anti-Inflammatory Drugs Market Summary
Study Period 2019 - 2030
Market Size (2025) USD 120.37 Billion
Market Size (2030) USD 181.00 Billion
CAGR (2025 - 2030) 8.50 %
Fastest Growing Market Asia Pacific
Largest Market North America
Market Concentration Low

Major Players

Anti Inflammatory Drugs Market Major Players

*Disclaimer: Major Players sorted in no particular order

Compare market size and growth of Anti Inflammatory Drugs Market with other markets in Healthcare Industry

Biotechnology

Pharmaceuticals

Healthcare IT

Medical Devices

Animal Health

Device Drug Combination

Anti Inflammatory Drugs Market Analysis

The Anti Inflammatory Drugs Market size is estimated at USD 120.37 billion in 2025, and is expected to reach USD 181.00 billion by 2030, at a CAGR of 8.5% during the forecast period (2025-2030).

The anti-inflammatory drugs market is poised for substantial growth, driven by rising incidences of autoimmune, inflammatory, and respiratory conditions and growing research for safer new anti-inflammatory drugs. Conditions like arthritis, allergies, and chronic inflammatory diseases are on the rise, driven by factors such as aging populations and lifestyle changes. Hence, the need for anti-inflammatory drug treatments is expected to increase, boosting the market’s growth over the forecast period.

There are alarming health disparities linked to chronic inflammation, particularly among vulnerable populations. For instance, in January 2024, a study spearheaded by a researcher from the University of Florida’s College of Public Health and Health Professions revealed that individuals grappling with chronic inflammation and living in poverty face a two-fold increased risk of succumbing to heart diseases and an almost three-fold heightened risk of cancer within the subsequent 15 years. Similarly, in 2023, a study spearheaded by Mainous showed 34.6% of US adults exhibiting signs of systemic inflammation. This shows the risk of inflammation and the need for proper treatment, which is expected to drive the market’s growth over the forecast period.

The growing accessibility of anti-inflammatory medications, driven by new product approvals and strategic partnerships aimed at developing innovative therapies, is anticipated to enhance market growth in the coming years. For example, in February 2024, AbbVie Inc. and OSE Immunotherapeutics SA established a strategic collaboration to further the development of OSE-230, a monoclonal antibody targeting chronic and severe inflammation, which was in the pre-clinical stage. This kind of trend is likely to expand the product offerings, contributing positively to market growth during the forecast period.

Therefore, the growing burden of inflammatory conditions and continuous innovations in anti-inflammatory drugs are expected to drive market growth globally. However, the side effects related to anti-inflammatory drugs and patent expiration of various branded drugs are expected to restrain market growth over the forecast period.

Anti-Inflammatory Drugs Industry Overview

The market is fragmented due to the availability of various anti-inflammatory drug manufacturing companies globally. The competitive landscape for the anti-inflammatory drugs market is dynamic and involves several key players, including pharmaceutical companies, biotechnology firms, and generics manufacturers. In addition, this competitive landscape is continuously evolving, driven by innovation, regulatory changes, and shifting market dynamics. Some of the major players in the market include AbbVie Inc., AstraZeneca PLC, F. Hoffmann-La Roche AG, Johnson & Johnson, and Pfizer Inc.

Anti-Inflammatory Drugs Market Leaders

  1. Johnson & Johnson

  2. Pfizer Inc.

  3. AbbVie Inc

  4. F. Hoffmann-La Roche AG

  5. AstraZeneca PLC

  6. *Disclaimer: Major Players sorted in no particular order
Anti-inflammatory Drugs Market Cocentration
Need More Details on Market Players and Competiters?
Download PDF

Anti-Inflammatory Drugs Market News

  • June 2024: Verona Pharma PLC received approval from the US Food and Drug Administration for Ohtuvayre (ensifentrine), a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adult patients. Ohtuvayre, a pioneering selective dual inhibitor, targets both phosphodiesterase 3 and phosphodiesterase 4 enzymes, merging bronchodilator properties with non-steroidal anti-inflammatory effects in a single molecule.
  • March 2024: AbbVie Inc. and Landos Biopharma Inc. entered a definitive agreement under which AbbVie would acquire Landos. Landos' investigational asset is NX-13, a first-in-class, oral NLRX1 agonist (a member of the NOD-like receptor family) with a bimodal mechanism of action (MOA), which is anti-inflammatory and facilitates epithelial repair.

Anti Inflammatory Drugs Market Report - Table of Contents

1. INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2. RESEARCH METHODOLOGY

3. EXECUTIVE SUMMARY

4. MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Incidences of Autoimmnue and Respiratory Conditions
    • 4.2.2 Growing Research for Safer New Anti-Inflammatory Drugs
  • 4.3 Market Restraints
    • 4.3.1 Side Effects of Anti-Inflammtory Drugs
    • 4.3.2 Patent Expiration
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5. MARKET SEGMENTATION (Market Size by Value - USD)

  • 5.1 By Treatment
    • 5.1.1 Arthritis
    • 5.1.2 Chronic Obstructive Pulmonary Disease (COPD)
    • 5.1.3 Multiple Sclerosis
    • 5.1.4 Inflammatory Bowel Disease (IBD)
    • 5.1.5 Asthma
    • 5.1.6 Tendonitis
    • 5.1.7 Other Treatments
  • 5.2 By Drug Class
    • 5.2.1 Anti-Inflammatory Biologics
    • 5.2.2 Non-steroidal Anti Inflammatory Drugs (NSAIDS)
    • 5.2.3 Corticosteroids
    • 5.2.4 Immune-selective Anti-inflammatory Derivative (ImSAID)
    • 5.2.5 Other Drug Classes
  • 5.3 By Sales Channel
    • 5.3.1 Prescription
    • 5.3.2 Over the Counter (OTC)
  • 5.4 Geography
    • 5.4.1 North America
    • 5.4.1.1 United States
    • 5.4.1.2 Canada
    • 5.4.1.3 Mexico
    • 5.4.2 Europe
    • 5.4.2.1 Germany
    • 5.4.2.2 United Kingdom
    • 5.4.2.3 France
    • 5.4.2.4 Italy
    • 5.4.2.5 Spain
    • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
    • 5.4.3.1 China
    • 5.4.3.2 Japan
    • 5.4.3.3 India
    • 5.4.3.4 Australia
    • 5.4.3.5 South Korea
    • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East and Africa
    • 5.4.4.1 GCC
    • 5.4.4.2 South Africa
    • 5.4.4.3 Rest of Middle East and Africa
    • 5.4.5 South America
    • 5.4.5.1 Brazil
    • 5.4.5.2 Argentina
    • 5.4.5.3 Rest of South America

6. COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Pfizer Inc.
    • 6.1.2 Amgen Inc.
    • 6.1.3 GSK PLC
    • 6.1.4 Johnson & Johnson
    • 6.1.5 Novartis AG
    • 6.1.6 F. Hoffmann-La Roche AG
    • 6.1.7 AbbVie Inc
    • 6.1.8 AstraZeneca PLC
    • 6.1.9 Merck & Co, Inc.
    • 6.1.10 Eli Lily and Company
  • *List Not Exhaustive

7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Subject to Availability
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments
You Can Purchase Parts Of This Report. Check Out Prices For Specific Sections
Get Price Break-up Now

Anti Inflammatory Drugs Industry Segmentation

As per the scope of the report, anti-inflammatory drugs are medications that reduce inflammation, which is the body’s natural response to injury or infection. These drugs are used to treat various conditions characterized by inflammation, including arthritis, asthma, inflammatory bowel disease, and other autoimmune disorders.

The anti-inflammatory drugs market is segmented by treatment, drug class, sales channel, and geography. By treatment, the market is segmented into arthritis, chronic obstructive pulmonary disease (COPD), multiple sclerosis, inflammatory bowel disease (IBD), asthma, tendonitis, and other treatments. By drug class, the market is segmented into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs), corticosteroids, immune-selective anti-inflammatory derivatives (ImSAID), and other drug classes. By sales channel, the market is segmented into prescription and over-the-counter (OTC). By geography, the market is segmented into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report also covers the estimated market sizes and trends for 17 countries across major regions globally. The report offers the value (USD) for all the above segments.

By Treatment Arthritis
Chronic Obstructive Pulmonary Disease (COPD)
Multiple Sclerosis
Inflammatory Bowel Disease (IBD)
Asthma
Tendonitis
Other Treatments
By Drug Class Anti-Inflammatory Biologics
Non-steroidal Anti Inflammatory Drugs (NSAIDS)
Corticosteroids
Immune-selective Anti-inflammatory Derivative (ImSAID)
Other Drug Classes
By Sales Channel Prescription
Over the Counter (OTC)
Geography North America United States
Canada
Mexico
Europe Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa GCC
South Africa
Rest of Middle East and Africa
South America Brazil
Argentina
Rest of South America
Need A Different Region or Segment?
Customize Now

Anti Inflammatory Drugs Market Research FAQs

How big is the Anti Inflammatory Drugs Market?

The Anti Inflammatory Drugs Market size is expected to reach USD 120.37 billion in 2025 and grow at a CAGR of 8.5% to reach USD 181.00 billion by 2030.

What is the current Anti Inflammatory Drugs Market size?

In 2025, the Anti Inflammatory Drugs Market size is expected to reach USD 120.37 billion.

Who are the key players in Anti Inflammatory Drugs Market?

Johnson & Johnson, Pfizer Inc., AbbVie Inc, F. Hoffmann-La Roche AG and AstraZeneca PLC are the major companies operating in the Anti Inflammatory Drugs Market.

Which is the fastest growing region in Anti Inflammatory Drugs Market?

Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).

Which region has the biggest share in Anti Inflammatory Drugs Market?

In 2025, the North America accounts for the largest market share in Anti Inflammatory Drugs Market.

What years does this Anti Inflammatory Drugs Market cover, and what was the market size in 2024?

In 2024, the Anti Inflammatory Drugs Market size was estimated at USD 110.14 billion. The report covers the Anti Inflammatory Drugs Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Anti Inflammatory Drugs Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.

Anti-inflammatory Drugs Industry Report

Statistics for the 2025 Anti Inflammatory Drugs market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Anti Inflammatory Drugs analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.